Terns Pharmaceuticals, Inc. Non-Controlling Interest

Non-Controlling Interest of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-Controlling Interest growth rates and interactive chart.


Highlights and Quick Summary

  • Non-Controlling Interest for the quarter ending December 31, 2020 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Non-Controlling Interest decreased by -100.0%
  • Annual Non-Controlling Interest for 2020 was $-518 Thousand (a 149.04% increase from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-Controlling Interest of Terns Pharmaceuticals, Inc.

Most recent Non-Controlling Interestof TERN including historical data for past 10 years.

Interactive Chart of Non-Controlling Interest of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Non-Controlling Interest for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.0 $-0.16 $-0.16 $-0.21 $-0.52
2019 $-0.21

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.